Key Takeaway
Wegovy is FDA-approved for weight loss while Mounjaro is approved for diabetes, yet both are used for weight management. Compare these two popular injectables.
Mounjaro (tirzepatide) produces more weight loss on average than Wegovy (semaglutide) despite being FDA-approved only for diabetes, while Wegovy holds the advantage of an official weight management indication and proven cardiovascular benefits..
This comparison comes up constantly at FormBlends because patients are hearing about both drugs and trying to figure out which is the smarter pick. The situation is a bit unusual: Wegovy is the one actually approved for weight loss, yet Mounjaro may be more effective at producing it. Let us sort through the details.
| Feature | Wegovy | Mounjaro |
|---|---|---|
| Active Ingredient | Semaglutide | Tirzepatide |
| Drug Class | GLP-1 receptor agonist | Dual GIP/GLP-1 receptor agonist |
| FDA-Approved For | Chronic weight management | Type 2 diabetes |
| Manufacturer | Novo Nordisk | Eli Lilly |
| Maximum Dose | 2.4 mg/week | 15 mg/week |
| Average Weight Loss | ~15-17% | ~15-22% |
| Cardiovascular Indication | Yes (SELECT trial[1]) | Not yet approved |
| List Price (monthly) | $1,300-$1,400/mo (brand) | $1,000-$1,200/mo (brand) |
How Wegovy Works
Wegovy delivers semaglutide at a dose of up to 2.4 mg per week through a once-weekly subcutaneous injection. Semaglutide is a GLP-1 receptor agonist that mimics the action of the naturally occurring incretin hormone GLP-1. When activated, these receptors trigger appetite suppression in the brain, slow the movement of food through the stomach, and improve insulin signaling.
For weight loss purposes, the appetite suppression and delayed gastric emptying are the most relevant effects. Patients consistently report feeling less hungry, thinking about food less often, and feeling full on smaller portions. These changes make it much easier to sustain a caloric deficit without the intense hunger that derails most diets.
Wegovy was the first semaglutide product approved specifically for weight management (June 2021), and it was the first GLP-1 to receive an FDA indication for cardiovascular risk reduction in overweight and obese patients (March 2024) based on the SELECT trial.
How Mounjaro Works
Mounjaro uses tirzepatide, a dual GIP/GLP-1 receptor agonist. While Wegovy activates only one incretin receptor, Mounjaro activates two: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) . For a complete cost breakdown, see our compare tirzepatide prices. Check out our see real Zepbound results for detailed data.
View data table
| Category | Overall Value Score | Detail |
|---|---|---|
| FormBlends | 92 | From $299/mo, physician-led |
| Hims/Hers | 78 | Consumer brand, varies |
| Ro | 75 | Telehealth platform |
| Calibrate | 70 | Metabolic health focus |
The addition of GIP receptor activation appears to enhance the metabolic response beyond what GLP-1 alone provides. GIP plays a role in nutrient sensing, fat storage regulation, and insulin release. When combined with GLP-1 signaling, the dual activation produces more pronounced appetite reduction and greater improvements in metabolic markers, including blood sugar, insulin sensitivity, and lipid levels.
Mounjaro was approved by the FDA in May 2022 for type 2 diabetes. Its weight loss counterpart, Zepbound, received approval for weight management in November 2023. Despite having a diabetes-only indication, Mounjaro is frequently prescribed off-label for weight loss.
Efficacy Comparison: Weight Loss Results
Mounjaro's clinical data shows a weight loss advantage, though the magnitude depends on dosing.
Not sure which GLP-1 is right for you?
Take a 2-minute assessment and get a personalized recommendation after licensed provider review.
Take the Assessment →The SURMOUNT-1 trial[2] (using the weight-loss-indicated version of tirzepatide) showed average weight loss of 15% at 5 mg, 19.5% at 10 mg, and 22.5% at 15 mg over 72 weeks . The SURPASS clinical program for diabetes showed similar trends, with significant weight loss as a co-benefit of blood sugar management.
Wegovy's STEP 1 trial[3] showed average weight loss of 14.9% at the 2.4 mg dose over 68 weeks . Subsequent STEP trials confirmed results in the 12-17% range across different populations, including patients with diabetes and those with cardiovascular risk factors.
In the SURPASS-2 trial[4], tirzepatide at all three doses was compared directly to semaglutide 1 mg (not the full Wegovy 2.4 mg dose). Tirzepatide produced greater weight loss and better A1C reductions at every dose level . While this doesn't perfectly replicate a Wegovy-vs-Mounjaro comparison, it strongly suggests that tirzepatide's dual mechanism provides a weight loss advantage.
Side Effects Comparison
Both medications share a common side effect profile rooted in their effects on the GI system:
- Nausea: Affects roughly 20-40% of patients on either medication during titration. Usually temporary.
- Diarrhea: Common with both, reported in 15-25% of patients.
- Vomiting: Most likely during dose increases.
- Constipation: Reported somewhat more frequently with tirzepatide in some trials.
- Decreased appetite: Nearly universal, which is the desired therapeutic effect for weight loss.
- Fatigue: Reported by a minority of patients on both drugs.
Both medications carry warnings for pancreatitis, gallbladder disease, kidney injury, diabetic retinopathy complications (in diabetic patients), and thyroid C-cell tumors (based on animal studies) . Patients with a personal or family history of medullary thyroid carcinoma shouldn't use either drug.
Our clinical team at FormBlends carefully monitors for side effects and adjusts dosing to help patients stay on treatment comfortably.
One practical difference worth noting is that Wegovy's five-step titration takes 16 to 20 weeks, while Mounjaro's six-step titration follows a similar timeline. Both are designed to help the body adapt gradually. Patients who rush the titration or skip dose levels tend to experience more intense nausea and vomiting, so we always encourage following the recommended schedule.
Long-Term Weight Maintenance
Both Wegovy and Mounjaro are intended as long-term treatments. Studies on semaglutide have shown that patients who stop Wegovy regain approximately two-thirds of their lost weight within one year . Similar patterns are expected with Mounjaro, though long-term discontinuation data for tirzepatide is still being collected.
This is an important consideration when choosing between the two. Since either medication needs to be taken indefinitely for sustained results, affordability and access over the long term should factor heavily into your decision. A medication that works brilliantly for six months but becomes unaffordable is ultimately less useful than one you can maintain for years.
At FormBlends, we help patients think beyond the first few months. We build treatment plans designed for sustainability, including the option to transition to compounded semaglutide or compounded tirzepatide if brand-name pricing becomes a barrier.
Cost Comparison
Both medications carry steep list prices. Wegovy costs approximately $1,300-$1,400/mo (brand) per month, while Mounjaro runs approximately $1,000-$1,200/mo (brand) per month.
Insurance dynamics differ between the two. Wegovy, with its weight management indication, may be covered by plans that include anti-obesity medications. Mounjaro, with its diabetes indication, is more commonly covered for patients with type 2 diabetes. Using Mounjaro off-label for weight loss without a diabetes diagnosis often means paying full price.
Neither medication is consistently affordable at list price, which is why many patients turn to compounded alternatives. FormBlends offers compounded semaglutide and compounded tirzepatide at prices that make these treatments accessible to more patients.
Who Is Wegovy Best For?
- Patients who want an FDA-approved weight loss medication (not off-label use)
- Those with cardiovascular risk who want the proven heart benefits from the SELECT trial
- Patients whose insurance specifically covers Wegovy for weight management
- Anyone who is already achieving good results on semaglutide
- Patients who prefer a drug with a longer history of use for weight management
Who Is Mounjaro Best For?
- Patients with type 2 diabetes who also want significant weight loss
- Those seeking the highest possible weight loss from a medication
- Patients who plateaued on semaglutide and want to try a different mechanism
- Those whose insurance covers Mounjaro for diabetes management
- Patients comfortable with off-label use if weight loss is the primary goal
Medical References
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. [PubMed | ClinicalTrials.gov | DOI]
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. [PubMed | ClinicalTrials.gov | DOI]
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. [PubMed | ClinicalTrials.gov | DOI]
- Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-515. [PubMed | DOI]
Frequently Asked Questions
FormBlends
FormBlends is a U.S. telehealth platform that prescribes compounded semaglutide and tirzepatide. Patients complete an online intake, a licensed provider reviews eligibility, and medication ships from a 503A compounding pharmacy. Monthly pricing starts at $199. Start your intake.
Which produces more weight loss?
Clinical data points to Mounjaro (tirzepatide) as the stronger weight loss agent, with average reductions of 15-22% compared to Wegovy's 15-17%. Individual responses vary, but the trend consistently favors tirzepatide.
Is it safe to use Mounjaro for weight loss when it's approved for diabetes?
Off-label prescribing is a standard and legal medical practice. Mounjaro's active ingredient, tirzepatide, is the same molecule used in Zepbound, which is FDA-approved for weight loss. The safety profile is well-established. But getting insurance to cover off-label use can be difficult.
Can I switch from Wegovy to Mounjaro?
Yes, your physician can manage a transition between the two. Since they use different active ingredients, you would typically start Mounjaro at its lowest dose (2.5 mg) and titrate up, even if you were on a high dose of Wegovy.
Do both medications require a prescription?
Yes, both Wegovy and Mounjaro require a prescription from a licensed healthcare provider. FormBlends connects patients with board-certified physicians who can evaluate your eligibility and prescribe the appropriate medication.
What if I have tried both and neither worked well enough?
Some patients don't respond as strongly to either medication on its own. In these cases, our physicians may explore higher doses, combination approaches with lifestyle modifications, or complementary therapies. The next generation of weight loss medications, including triple agonists currently in clinical trials, may offer additional options in the near future. Our team stays current with the latest developments and will always present the best available options.
The Wegovy versus Mounjaro decision is ultimately a conversation between you and your physician. Both medications represent a dramatic leap forward in weight management, and either one can produce life-changing results for the right patient. What matters most is getting started with one of them and sticking with treatment long enough to see meaningful progress.
Ready to explore your options? Start your free consultation with FormBlends today. Our physicians will review your health profile and help you choose the right treatment approach, whether that's semaglutide, tirzepatide, or a combination strategy.